Capsule Summary Slidesets

Share

Program Content

Activities

  • Luspatercept for Anemia in MF
    Phase II Study: Luspatercept for Treatment of Myelofibrosis-Associated Anemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2019

    Expires: December 06, 2020

  • APR-246 + AZA in MDS/AML
    Phase Ib/II Trial of APR-246 + Azacitidine in TP53-Mutant MDS and AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2019

    Expires: December 17, 2020

  • TP53 Mutant MDS/AML: APR-246 + Aza
    GFM Phase II Study of APR-246 Plus Azacitidine in TP53-Mutated MDS and AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2019

    Expires: December 17, 2020

  • MEDALIST: Luspatercept in MDS
    Updated Analysis From the Phase III MEDALIST Trial of Luspatercept to Treat Anemia in Lower-Risk RBC Transfusion-Dependent MDS With Ring Sideroblasts
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2019

    Expires: December 13, 2020

  • VEN ± AZA in MDS
    Phase Ib Study: Venetoclax With or Without Azacitidine for Treatment of Relapsed/Refractory Myelodysplastic Syndrome
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company